- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT05338775
Исследование талкетамаба и теклистамаба в комбинации с ингибитором рецептора запрограммированной клеточной смерти-1 (PD-1) для лечения участников с рецидивирующей или рефрактерной множественной миеломой (TRIMM-3)
Исследование фазы 1b биспецифических антител для перенаправления Т-клеток в сочетании с ингибированием контрольной точки для лечения участников с рецидивирующей или рефрактерной множественной миеломой
The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 inhibitor.
Обзор исследования
Статус
Вмешательство/лечение
Тип исследования
Регистрация (Действительный)
Фаза
- Фаза 1
Расширенный доступ
Контакты и местонахождение
Места учебы
-
-
-
Dresden, Германия, 01307
- Universitatsklinikum Carl Gustav Carus Dresden
-
Hamburg, Германия, 20246
- Universitaetsklinikum Hamburg Eppendorf
-
Heidelberg, Германия, 69120
- Universitaetsklinikum Heidelberg
-
Würzburg, Германия, 97080
- Universitatsklinikum Wurzburg
-
-
-
-
-
Badalona, Испания, 08916
- Hosp. Univ. Germans Trias I Pujol
-
Madrid, Испания, 28040
- Hosp Univ Fund Jimenez Diaz
-
Pamplona, Испания, 31008
- Clinica Univ. de Navarra
-
Salamanca, Испания, 37007
- Hosp Clinico Univ de Salamanca
-
-
-
-
Colorado
-
Denver, Colorado, Соединенные Штаты, 80218
- Colorado Blood Cancer Institute
-
-
New York
-
New York, New York, Соединенные Штаты, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Соединенные Штаты, 10029
- Icahn School of Medicine at Mount Sinai
-
New York, New York, Соединенные Штаты, 10011
- The Blavatnik Family Chelsea Medical Center at Mount Sinai
-
-
North Carolina
-
Winston-Salem, North Carolina, Соединенные Штаты, 27157
- Wake Forest Baptist Medical Center
-
-
Tennessee
-
Nashville, Tennessee, Соединенные Штаты, 37203
- Sarah Cannon Research Institute
-
Nashville, Tennessee, Соединенные Штаты, 37232
- Vanderbilt Ingram Cancer Center
-
-
-
-
-
Montpellier, Франция, 34295
- CHU de Montpellier Hopital Saint Eloi
-
Nantes, Франция, 44093
- CHU de Nantes hotel Dieu
-
Poitiers, Франция, 86021
- CHU Poitiers - Hopital la Miletrie
-
Toulouse, Франция, 31059
- Institut Universitaire du Cancer Toulouse Oncopole
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Have documented initial diagnosis of multiple myeloma according to International Myeloma Working Group (IMWG) diagnostic criteria
- Participants with relapsed or refractory disease that are not a candidate for available therapy with established clinical benefit
- Have measurable disease at screening as defined by at least 1 of the following: a) Serum M-protein level greater than or equal to (>=) 0.5 grams per deciliter (g/dL); b) Urine M-protein level >= 200 milligrams (mg) per 24 hours; c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >= 10 milligrams/deciliter (mg/dL) and abnormal serum Ig kappa lambda FLC ratio
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
Exclusion Criteria:
- Prior antitumor therapy within 21 days prior to the first dose of study treatment (proteasome inhibitor [PI] therapy or radiotherapy within 14 days, immunomodulatory drug (IMiD) agent therapy within 7 days, gene -modified adoptive cell therapy or autologous stem cell transplant within 3 months)
- Prior therapy with PD-1 inhibitors, allogeneic stem cell transplant or solid organ transplant
- Active plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes), or primary light chain amyloidosis
- Active Central Nervous System (CNS) involvement or exhibition of clinical signs of meningeal involvement of multiple myeloma. If either is suspected, brain magnetic resonance imaging (MRI) and lumbar cytology are required
- Live, attenuated vaccine within 4 weeks before the first dose of study treatment
- Non-hematologic toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (<=) 1 (except alopecia [any grade] or peripheral neuropathy to Grade <= 2)
- Received a cumulative dose of corticosteroids equivalent to >= 140 milligrams (mg) of prednisone within the 14-day period before the start of study treatment administration
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Нерандомизированный
- Интервенционная модель: Последовательное назначение
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Part 1: Dose Escalation
Participants will receive either talquetamab (treatment regimen A) or teclistamab (treatment regimen B) with a PD-1 inhibitor biweekly. |
Talquetamab will be administered as a subcutaneous (SC) injection. Teclistamab will be administered as a SC injection. The PD-1 inhibitor will be administered as an intravenous injection. |
|
Экспериментальный: Part 2: Dose Expansion
Participants will receive either treatment regimen A or treatment regimen B with a PD-1 inhibitor at the dose levels identified in Part 1. |
Talquetamab will be administered as a subcutaneous (SC) injection. Teclistamab will be administered as a SC injection. The PD-1 inhibitor will be administered as an intravenous injection. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Number of Participants with Adverse Events (AEs)
Временное ограничение: Up to 2 years 5 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 2 years 5 months
|
|
Number of Participants with Adverse Events (AEs) by Severity
Временное ограничение: Up to 2 years 5 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening, and Grade 5= Death related to adverse event. |
Up to 2 years 5 months
|
|
Number of Participants with Abnormalities in Clinical Laboratory Assessments
Временное ограничение: Up to 2 years 5 months
|
Number of participants with abnormalities in clinical laboratory assessments (serum chemistry and hematology) will be reported. |
Up to 2 years 5 months
|
|
Number of Participants with Dose-Limiting Toxicity (DLTs)
Временное ограничение: Up to 2 years 5 months
|
The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity. |
Up to 2 years 5 months
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Overall Response Rate (ORR)
Временное ограничение: Up to 2 years 5 months
|
ORR is defined as the percentage of participants who achieve partial response (PR) or better according to the International Myeloma Working Group (IMWG) 2016 criteria. |
Up to 2 years 5 months
|
|
Very Good Partial Response (VGPR) or Better Response Rate
Временное ограничение: Up to 2 years 5 months
|
VGPR or better response rate is defined as the percentage of participants who achieve a VGPR or better response (stringent complete response [sCR]+ complete response [CR]+VGPR) according to the IMWG 2016 criteria. |
Up to 2 years 5 months
|
|
Complete Response (CR) or Better Response Rate
Временное ограничение: Up to 2 years 5 months
|
CR or better response rate is defined as the percentage of participants who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria. |
Up to 2 years 5 months
|
|
Stringent Complete Response (sCR) Rate
Временное ограничение: Up to 2 years 5 months
|
sCR rate is defined as the percentage of participants who achieve an sCR according to the IMWG 2016 criteria. |
Up to 2 years 5 months
|
|
Duration of Response
Временное ограничение: Up to 2 years 5 months
|
Duration of response is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), per IMWG 2016 criteria or death due to any cause, whichever occurs first. |
Up to 2 years 5 months
|
|
Time to Response
Временное ограничение: Up to 2 years 5 months
|
Time to response is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant has met all criteria for PR or better. |
Up to 2 years 5 months
|
|
Serum Concentrations of Talquetamab
Временное ограничение: Up to 2 years 5 months
|
Serum samples will be analyzed to determine concentrations of Talquetamab using validated, specific, and sensitive immunoassay methods. |
Up to 2 years 5 months
|
|
Serum Concentrations of Teclistamab
Временное ограничение: Up to 2 years 5 months
|
Serum samples will be analyzed to determine concentrations of Teclistamab using validated, specific, and sensitive immunoassay methods. |
Up to 2 years 5 months
|
|
Serum Concentrations of PD-1 Inhibitor
Временное ограничение: Up to 2 years 5 months
|
Serum samples will be analyzed to determine concentrations of PD-1 inhibitor using validated, specific, and sensitive immunoassay methods. |
Up to 2 years 5 months
|
|
Number of Participants with Anti-Talquetamab Antibodies
Временное ограничение: Up to 2 years 5 months
|
Number of participants with anti-talquetamab antibodies will be reported. |
Up to 2 years 5 months
|
|
Number of Participants with Anti-Teclistamab Antibodies
Временное ограничение: Up to 2 years 5 months
|
Number of participants with anti-teclistamab antibodies will be reported. |
Up to 2 years 5 months
|
|
Number of Participants with Anti-PD-1 Inhibitor Antibodies
Временное ограничение: Up to 2 years 5 months
|
Number of participants with anti-PD-1 inhibitor antibodies will be reported. |
Up to 2 years 5 months
|
Соавторы и исследователи
Следователи
- Директор по исследованиям: Janssen Research and Development, LLC Clinical Trial, Janssen Research & Development, LLC
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- CR109168
- 2021-005073-22 (Номер EudraCT)
- 64407564MMY1005 (Другой идентификатор: Janssen Research & Development, LLC)
- 2022-502681-24-00 (Идентификатор реестра: EUCT number)
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .